Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (111-120 of 466) with videos related to

Pageof 47
Sort By:
Infectious Agents and Cancer|February 25, 2021
Protection strategy against outbreak of COVID-19 at a tertiary hematology-oncology: strengths and pitfallsDominic Kaddu-Mulindwa, Lorenz Thurner, Moritz Bewarder, et al.
Hemasphere|October 30, 2025
Overall survival outcomes with first-line continuous ibrutinib and fixed-duration ibrutinib-venetoclax treatments in patients with chronic lymphocytic leukemia: Comparison with an age-matched European populationPaolo Ghia, Loic Ysebaert, Ann Janssens, et al.
Cancer Research|November 19, 2009
A novel paradigm to trigger apoptosis in chronic lymphocytic leukemiaSandra Loeder, Thorsten Zenz, Andrea Schnaiter, et al.
Leukemia & Lymphoma|September 18, 2015
Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study groupValentin Goede, Jasmin Bahlo, Viktoria Chataline, et al.
Blood|March 26, 2010
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemiaMaike Buchner, Constance Baer, Gabriele Prinz, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 30, 2010
Chronic lymphocytic leukemia: new concepts for future therapyWilliam G Wierda, Nicholas Chiorazzi, Claire Dearden, et al.
European Journal of Haematology|July 14, 2011
Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemiaKai Uwe Chow, Soo-Zin Kim, Nils von Neuhoff, et al.
Leukemia & Lymphoma|April 7, 2009
Chronic lymphocytic leukemia and 13q14: miRs and moreDaniel Mertens, Angela Philippen, Melanie Ruppel, et al.
Leukemia & Lymphoma|April 7, 2009
Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathwayThorsten Zenz, Julia Mohr, Jennifer Edelmann, et al.
Haematologica|August 2, 2007
Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survivalStephan Stilgenbauer, Sandrine Sander, Lars Bullinger, et al.
Pageof 47

Showing results (111-120 of 466) with videos related to

Sort By:
Pageof 47
Infectious Agents and Cancer|February 25, 2021
Protection strategy against outbreak of COVID-19 at a tertiary hematology-oncology: strengths and pitfallsDominic Kaddu-Mulindwa, Lorenz Thurner, Moritz Bewarder, et al.
Hemasphere|October 30, 2025
Overall survival outcomes with first-line continuous ibrutinib and fixed-duration ibrutinib-venetoclax treatments in patients with chronic lymphocytic leukemia: Comparison with an age-matched European populationPaolo Ghia, Loic Ysebaert, Ann Janssens, et al.
Cancer Research|November 19, 2009
A novel paradigm to trigger apoptosis in chronic lymphocytic leukemiaSandra Loeder, Thorsten Zenz, Andrea Schnaiter, et al.
Leukemia & Lymphoma|September 18, 2015
Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study groupValentin Goede, Jasmin Bahlo, Viktoria Chataline, et al.
Blood|March 26, 2010
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemiaMaike Buchner, Constance Baer, Gabriele Prinz, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 30, 2010
Chronic lymphocytic leukemia: new concepts for future therapyWilliam G Wierda, Nicholas Chiorazzi, Claire Dearden, et al.
European Journal of Haematology|July 14, 2011
Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemiaKai Uwe Chow, Soo-Zin Kim, Nils von Neuhoff, et al.
Leukemia & Lymphoma|April 7, 2009
Chronic lymphocytic leukemia and 13q14: miRs and moreDaniel Mertens, Angela Philippen, Melanie Ruppel, et al.
Leukemia & Lymphoma|April 7, 2009
Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathwayThorsten Zenz, Julia Mohr, Jennifer Edelmann, et al.
Haematologica|August 2, 2007
Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survivalStephan Stilgenbauer, Sandrine Sander, Lars Bullinger, et al.
Pageof 47